Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy.
Saved in:
| Title: | Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy. |
|---|---|
| Authors: | Chueh, Chen-Han1 (AUTHOR), Tsai, Yi-Wen1 (AUTHOR) ywtsai@nycu.edu.tw, Chen, Zi-Rong1 (AUTHOR), Shiu, Ming-Neng1,2 (AUTHOR), Wen, Yu-Wen3 (AUTHOR), Chiang, Nai-Jung4,5 (AUTHOR) njchiang@vghtpe.gov.tw |
| Source: | PharmacoEconomics. Mar2023, Vol. 41 Issue 3, p307-319. 13p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 11707690 |
|---|---|
| DOI: | 10.1007/s40273-022-01227-6 |
